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Abstract 
Background: Recently different forms of nanographene were proposed as the material with high anticancer poten-
tial. However, the mechanism of the suppressive activity of the graphene on cancer development remains unclear. We 
examined the effect of oxygenated, reduced and pristine graphene on the gene expression in glioblastoma U87 cell 
line.
Results: Conducting microarrays and RT-qPCR analysis we explored that graphene oxide (rather than reduced gra-
phene oxide and pristine graphene) down-regulates the mRNA expression of mitochondrial oxidative phosphoryla-
tion (OXPHOS) nuclear genes of complexes I, III, IV and V. The presented results provide first evidence for the hypoth-
esis that the suppressed growth of GBM can be the consequence of down-regulation of OXPHOS protein expression 
and decreased ATP level.
Conclusions: We suggest that changes in the expression of OXPHOS genes identified in our study may mediate 
the anti-proliferative and anti-migratory effects of graphene oxide in glioblastoma cells. However, further investiga-
tions with different cell lines, regarding expression, regulation and activity of OXPHOS genes identified in our study is 
necessary to elucidate the mechanism mediating the anti-proliferative and anti-migratory effects of graphene oxide 
in glioblastoma cells.
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Background
Graphene is a nanomaterial with unique properties and 
great application potential. It is expected to revolution-
ize various medical fields, including oncology. Many 
biomedical applications of graphene and its derivatives 
have been proposed in cancer diagnosis [1], biomedi-
cine [2], photothermal therapy [3, 4], cancer cell imaging 
[5], and drug delivery [6, 7]. Graphene is a single atomic 
layer of sp2-bonded carbon nanostructure [8], with a 
higher ratio of peripheral to central carbon atoms com-
pared to similar nanomaterials. Graphene appears to be 
biocompatible, with preferential affinity to the cell mem-
brane, and is less toxic than other carbon nanoparticles 
[9, 10]. Regarding biomedical applications, graphene 
oxide (GO) and reduced graphene oxide (rGO) are the 
most commonly described [11]. One of the crucial differ-
ences between the forms is their hydrophobic (rGO) or 
hydrophilic (GO) characteristic [12]. We previously per-
formed the comparative toxicity studies, evaluating their 
effect on organism development and cancer growth in 
both in  vitro and in  vivo models [13–16]. Furthermore, 
it has been reported that nanocarbons can affect cell 
morphology and viability and can also influence DNA 
damage, RNA efflux and gene expression [1, 17, 18]. 
Hydrophilic GO possesses a large aromatic surface with 
reactive COOH and OH groups which facilitate connec-
tions with cellular molecules [19]. Compared to other 
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graphene types, GO is smaller, possesses smooth edges 
and forms more regular structures. Based on the compar-
ative studies previously published, we decided to perform 
the presented experiments using 100 nm graphene plate-
lets in the concentration of 25  ppm [12]. The detailed 
description of graphene structure and its distribution 
within glioblastoma cells were previously extensively ana-
lyzed [12].
It was demonstrated that GO effectively inhibits tumor-
sphere formation in breast, ovarian, prostate, lung, pan-
creas and brain cell lines [16, 17]. GO can suppress the 
development and migration of cancer cells by impairing 
mitochondrial respiration [20, 21]. Also, in  vivo studies 
presented GO to be a suppressing agent of cancer devel-
opment [22].
In the chicken embryo model, we have demonstrated 
that GO and rGO significantly decreased volume and 
weight of the glioblastoma tumor (GBM) [15, 23, 24]. 
Furthermore, it has been indicated and that functional-
ized GO might be applied as the drug delivery agent in 
the GBM therapy [25]. Moreover, after treatment with 
rGO, the apoptosis markers were significantly increased, 
suggesting that rGO may be involved in the inhibition of 
tumor development.
Importantly, graphene can directly and physically inter-
act with DNA, causing the deregulation of gene expres-
sion [17]. GO treatment at concentrations of 10 and 
100 mg/mL altered gene expression patterns, and medi-
ated DNA-damage control, cell apoptosis, cell cycle, and 
metabolism [1].
Based on these investigations and continuing our pre-
vious research indicating the suppressive effect of GO 
and rGO on GBM growth, we hypothesized that different 
graphene forms (GO, rGO and pG—pristine graphene) 
may inhibit GBM development by regulation of the genes 
encoding proteins responsible for mitochondrial oxida-
tive phosphorylation (OXPHOS). The presented study is 
considered as the first step in validating this hypothesis.
Results
Using microarrays, we have analyzed transcriptomic 
patterns elicited in GBM cells by treatment with either 
GO, rGO or pG. GO surface profile is presented on 
Fig. 1. GO treatment increased the expression of 90 and 
decreased the expression of 227 known transcripts in 
GBM cells. All probes reporting statistically significant 
differences between experimental groups are presented 
in Additional file 1. The treatment of GBM cells with pG 
changed the expression of FOS and C8orf4 genes, while 
GR changed only the expression of the FOS gene. Thus, 
we propose that rGO and pG do not notably modulate 
mRNA expression levels, at least under the conditions of 
the current experiment. Using the Enrichr tool [26] we 
performed enrichment analysis on the list of genes dereg-
ulated by GO treatment.
We have identified multiple overrepresented terms 
(Additional file  2) including: 120 biological processes, 
25 cellular components, 17 molecular functions, 42 bio-
logical pathways, 291 unique transcriptional regulators 
(Additional file 2) and 13 unique hub proteins or protein 
complexes. Data from several independent databases, 
queried in our enrichment analysis, showed that genes 
involved in the activity of the electron transport chain 
were robustly overrepresented in our list of differentially 
expressed genes.
Additional file 1 presents identified terms related to the 
electron transport chain, which were characterized in our 
analysis by the highest adjusted P-values of enrichment. 
Figure 2 presents the differentially expressed genes asso-
ciated with the electron transport chain pathway.
Microarray results were validated by RT-qPCR. We 
have analyzed 10 genes involved in the electron transport 
chain. The results of RT-qPCR analysis confirmed the 
findings of the microarray study (Fig. 3). The correlation 
coefficient between the results of RT-qPCR and microar-
ray analyses, calculated using the Spearman rank correla-
tion method, was equal to 0.88.
Fig. 1 Surface morphology and line profile of graphene oxide nanoparticles. Analyzed using atomic force microscopy
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Fig. 2 Differentially expressed genes connected to electron transport chain pathway. The scheme shows electron transport chain pathway and 
was downloaded from WikiPathways database. The blue, downward-pointing arrows show genes, which were down-regulated in GBM cells after 
GO treatment. Here, we list differentially expressed genes, that are not shown on the scheme, but that are connected to electron transport chain: 
ATP5EP2 (connected to overrepresented term: ATP synthesis coupled proton transport—GO:0015986), COA6 (cytochrome-c oxidase activity—
GO:0004129), COX14 (Respiratory electron transport—Reactome), UQCRHL (Electron Transport Chain (Homo sapiens)—WikiPathways), UQCRQ 
(Electron Transport Chain (Homo sapiens)—WikiPathways), USMG5 (mitochondrial proton-transporting ATP synthase complex—GO:0005753)
Fig. 3 RT-qPCR analysis of selected, OXPHOS-related differentially expressed genes. Here we show relative (GO-treated vs. control cells) expression 
of given gene. Expression values for the given gene were first normalized to expression values of reference genes, and then compared between 
experimental groups. Expression ratios were calculated using the REST 2009 software tool. Results are presented as whisker-box plots where 
the box area encompasses 50% of all observations, the dashed line represents the sample median and the whiskers represent the outer 50% of 
observations. The black solid line defines the value of no change in relative expression. Statistical significance: *p < 0.05, ***p < 0.001
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Discussion
It was already widely presented that GO suppresses 
the growth of the different cancers in both in vivo and 
in  vitro studies, however, the mechanism responsible 
for the inhibition remains unknown [22, 25, 27, 28].
In the present work, we used U87 cell line from the 
American Type Culture Collection. The studies of U87 
cell markers [29] and recent genetic profiling and tran-
scriptome analysis in human glioma cell lines indicate 
that this cell line is a glioblastoma cell line [30]. The 
comparison studies between different glioma cell lines 
treated with graphene were previously evaluated in our 
laboratory and thoroughly described [6].
Using microarrays, we showed for the first time on 
the U87 cell line, that GO (but not rGO and pG) down-
regulates the genes responsible for OXPHOS. The dif-
ferentially expressed genes detected in the presented 
experiments, after GO, rGO and pG treatment of GBM 
cells, are reported in Additional file  1 and Fig.  3. Fig-
ure  3 shows the identified genes for which the differ-
ential expression was confirmed via RT-qPCR analysis. 
Both experimental methods show that GO down-reg-
ulates the mRNA of OXPHOS nuclear genes of com-
plexes I, III, IV and V.
Interestingly, our experiments did not detect any 
changes in the expression of the analyzed genes after 
rGO and pG treatment. We assume that the observed 
impact of GO on gene expression is the result of its 
unique chemo-physical properties. Compared to rGO 
and pG, GO is hydrophilic and possesses reactive 
COOH and OH groups, which facilitates its connec-
tion to DNA [1, 19, 31]. The anticancer activity of rGO 
and pG observed in other studies [14, 15] could be the 
result of different cytotoxic mechanisms. In contrast 
to GO, rGO and pG forms remain surrounded by the 
active and conductive delocalized electrons, which may 
inhibit cell viability via ROS generation and/or affect 
membrane integrity [32, 33]. Moreover, hydrophobic 
rGO shows lower water solubility than GO and fre-
quently aggregates in salt-containing physiological buff-
ers due to its different electrostatic charge [30]. rGO 
commonly forms nonspecific bindings to proteins and 
lipids. Strong hydrophobic interactions of rGO with the 
cell membrane lipids might result in its accumulation, 
which may eventually lead to cell membrane damages. 
Surface modifications of graphene (like addition of oxy-
gen groups) improve its solubility in water. GO does 
not affect cell membranes as effectively as rGO, so it 
remains longer within the cells and consequently it may 
impact the cell molecular mechanisms [30]. Neverthe-
less, the cytotoxic activity mechanisms for rGO and pG 
need to be evaluated; however, it was not the primary 
interest of the presented study.
The function of electron transport chain Complex I is 
to remove electrons from NADH and transfer them to 
ubiquinone. It is one of the main sites of ROS produc-
tion [34]. Among the other differentially regulated genes 
revealed in the microarray analysis, RT-qPCR confirmed 
that GO modulates expression of the following genes: 
NDUFA1, NDUFB3 and NDUFS4. The proteins encoded 
by those genes were described as critical for complex 
I functioning [35]. Decreased Complex I activity may 
reduce cancer growth and induce cell death via oxidative 
stress [36].
Complex III is involved in the GBM development and 
mediates resistance to drugs for glioma [37, 38]. Tran-
scripts of UQCR11 and UQCRQ, the down-regulation of 
which was verified in our study via RT-qPCR, were also 
described to be regulated in carcinoma [39, 40]. Muta-
tions of genes involved in complex III and IV activity 
were shown to be associated with glioblastoma growth 
[38]. Moreover, increased cytochrome c oxidase (Com-
plex IV) activity was associated with the acquisition of 
chemoresistance in GBM [41]. Our RT-qPCR analysis 
confirmed that mRNAs of COX7B and COX17 genes, 
which protein products participate in Complex IV, were 
down-regulated Interestingly COX17 was proposed as 
the therapeutic target in lung cancer [42], while COX7B 
was shown to be overexpressed in carcinoma and its 
expression was decreased by anti-tumor agents in the 
glioblastoma treatment [43]. Complex V functions as an 
ATP synthase. ATP5E transcript that was identified as 
down-regulated in our experiment was proposed as the 
tumor marker in thyroid cancer [44].
We hypothesized that the significant changes in gene 
expression might notably affect the tumor development 
and OXPHOS activity. Our results, presenting down-reg-
ulation of OXPHOS mRNA expression correspond with 
the protein level changes reported by Zhou et al. [21]. The 
authors showed decreased protein level in the mitochon-
drial electron transfer chain complexes in breast cancer 
cells exposed to GO via quantitative proteomic analysis. 
Interestingly, they showed that GO treatment increased 
COX17 protein level, while we found down-regulation of 
COX17 mRNA. Unfortunately, the publication did not 
include the data of other proteins encoded by genes with 
deregulated mRNAs detected in our study. Most of the 
other genes presented in the abovementioned study were 
down-regulated. It was presented that the proteins of the 
subunits comprising every complex were also therefore 
down-regulated. Also, in another work [20], it was shown 
that graphene oxide inhibits the activity of electron trans-
port complexes I, III and IV in a dose-dependent manner. 
Similarly, we found that GO inhibits the expression of 
genes encoding proteins belonging to the same OXPHOS 
complexes. It was concluded [20] that the activity of the 
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electron transport chain proteins was decreased as the 
nanographene affected the iron sulfur centers of the 
complexes. Our research indicates that the activity of 
OXPHOS may also be decreased via the down-regulation 
of nuclear genes.
Deregulation of cellular energy metabolism is nec-
essary to effectively support neoplastic proliferation 
(reviewed [45]). It was described that some of the can-
cer cells meet their energy demands mostly by glyco-
lysis followed by lactic acid fermentation, as opposed to 
typical cells, which preferentially use mitochondrial 
oxidative phosphorylation. This phenomenon is known 
as a Warburg effect [46]. Nevertheless, both, the men-
tioned mechanism and a high ATP level are required for 
the growth of cancer [21]. GO significantly decreased 
the proliferation of MDA-MB-231, MDA-MB-436 and 
SK-BR-3 breast cancer cells via the down-regulation of 
OXPHOS activity without any changes in glycolysis [21]. 
Decreased OXPHOS activity inhibits the migratory and 
invasive characteristics of cancer [21].
Moreover, the growing GBM is composed of different 
subpopulations of cells and the population of cancer stem 
cells (CSC) seems to be crucial for tumor initiation and 
self-renewal [47, 48]. Independent of the glycolysis and 
differently from differentiated tumor cells, CSC activity 
fully depends on OXPHOS [48, 49]. Therefore, the inhibi-
tion of OXPHOS in GBM may suppress tumor expansion 
via the disruption of CSC functioning [48].
Disrupted OXPHOS significantly reduces ATP pro-
duction and cytoskeletal function, which consequently 
affects the migratory and invasive activity of cancer [20]. 
Decreased energy production in cancer cells impairs their 
metastasis potential. Migration of the cells is the result of 
the lamellipodia or filopodia movement, which is regu-
lated by the cytoskeleton [20, 50]. It was also shown that 
GO disrupts F-actin cytoskeletal functioning [20, 21]. 
In vivo experiments in mice revealed that GO inhibits the 
migration of metastatic cancer nodules [21]. Our results 
provide further support for the hypothesis that the sup-
pressed growth of GBM can be the result of down-reg-
ulation of OXPHOS protein expression and decreased 
ATP levels. Such growth suppression may inhibit cancer 
migration and metastasis.
We also propose that down-regulation of the expres-
sion of nuclear genes encoding mitochondrial pro-
teins may be a result of the mitochondrial dysfunction 
caused by GO. We previously reported that chicken 
embryo cells treated with different types of graphene 
possessed disrupted mitochondria [16] and GBM 
cells grown in ovo and treated with GO and rGO had 
degraded mitochondria [15]. Furthermore, mitochon-
drial fluorescence was quenched by graphene, suggest-
ing that graphene nanoparticles were located inside 
and around the mitochondria of cancer cells [18]. The 
overproduction of ROS by the mitochondrial electron 
transport chain may be one of the mechanisms of GO 
mediated mitochondria disruption. It was suggested 
[51] that ROS can be involved in the toxic effects of 
graphene-based nanomaterials. The other researchers 
indicated that plasma membrane damage and oxidative 
stress are the key factors in graphene-induced cyto-
toxicity of HepG2 cells [52]. In murine macrophages, 
GO-induced cytotoxicity through depletion of the 
mitochondrial membrane potential, increasing the 
production of intracellular ROS and triggering apop-
tosis [53]. Interestingly, mitochondrial dysfunction and 
altered dynamics (processes of fusion and fission) were 
shown to regulate migration and invasion of the cancer 
cells [54]. Importantly, it was shown that dysfunctional 
mitochondria can regulate nuclear gene expression 
(reviewed [55]). Gene expression changes can be 
induced by iron-sulfur cluster (ISC) biogenesis, which 
is altered in dysfunctional mitochondria [56]. Based on 
previous studies and our present research, we speculate 
that GO affects mitochondrial function of cancer cells, 
not only via a previously proposed direct impact on 
ROS generation, but also via modulation of expression 
of the genes involved in mitochondrial activity.
Conclusions
We demonstrated that GO treatment caused changes 
in the mRNA expression of genes involved in OXPHOS 
in GBM cells, while pG and rGO had no effect. We sug-
gest that changes in the expression of OXPHOS genes 
identified in our study comprise an interesting candidate 
mechanism which explains the anti-proliferative and 
anti-migratory effects of GO in GBM cells. Further stud-
ies of tumor proliferation, protein expression panel and 
the effects of knock-out of genes identified in current 
study, are still necessary to further evaluate the presented 
hypothesis.
Methods
Nanoparticles
pG powder, produced by liquid-phase exfoliation of 
graphite, was purchased from Skyspring Nanomaterials 
(Huston, TX, USA). GO and rGO were obtained from 
the Institute of Electronic Materials Technology (War-
saw, Poland). GO was prepared by a modified Hummers 
method from natural graphite flakes (Asbury Carbon). 
The Zeta potential of pG, GO and rGO suspended in 
milli-Q water was measured on a Zetasizer Nano-ZS90 
(Malvern Instruments, Worcestershire, UK). For details 
of graphene powder preparations cf. [16].
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AFM graphene oxide structure analysis
200  µl of graphene oxide suspension was placed on the 
silicic substrate, previously polished and cleaned in the 
preparation for atomic force microscope (AFM) meas-
urement. The samples were dried in an exicator for 
24 h. Afterwards the surface topography of the prepared 
samples was analyzed in the AFM measurement system 
(Nanosurf FLEX-Axiom). The scan sizes areas were ana-
lyzed in the range of 5 × 5 to 20 × 20 µm. The measure-
ments were conducted in the tapping mode. The time of 
line scanning and amplitude of oscillation were matched 
properly for each analyzed sample.
Cell culture and treatment
Human glioblastoma cell line U87 was purchased from 
the American Type Culture Collection (Manassas, VA, 
USA). The cells were maintained in Dulbecco’s modi-
fied Eagle’s culture medium containing 10% fetal bovine 
serum (Life Technologies, Houston, TX, USA), 1% peni-
cillin and streptomycin (Life Technologies) at 37  °C in 
a humidified atmosphere of 5% CO2/95% air in a DH 
AutoFlow CO2 Air-Jacketed Incubator (NuAire, Plym-
outh, MN, USA). 0.01  g of graphene (pG, GO or rGO) 
powder was dissolved in 10 mL of milli-Q water to obtain 
concentration of 1000  ppm. Then, the prepared stocks 
of graphene were added to Dulbecco’s Modified Eagle’s 
culture Medium to obtain the concentration of 25  ppm 
of each type of graphene. U-87 MG glioblastoma cells 
were seeded in 75  cm2 culture flasks (1 × 106 cells per 
flask) and incubated to reach 70% confluency. Then, the 
cells were washed by phosphate-buffered saline (Sigma-
Aldrich) and subsequently Modified Eagle’s culture 
Medium with addition of graphene was added into each 
flask. After 24 h, cells were disassociated by 0.25% trypsin 
with EDTA, harvested and suspended in fresh DMEM 
medium. Then the cells were centrifuged at 1200 rpm for 
5 min, washed with phosphate buffered saline and centri-
fuged to obtain a pellet. The cells were suspended in RNA 
later (Thermo Fisher Scientific, USA) and stored at 4  °C 
for the analysis. For the control, the cells were cultured in 
the Dulbecco’s modified Eagle’s culture medium contain-
ing 10% fetal bovine serum (Life Technologies, Houston, 
TX, USA) without the addition of graphene.
RNA isolation
Total RNA was isolated from 1 × 106 cells using Blood/
Cell RNA Mini Kit (Syngen, Wroclaw, Poland) according 
to the manufacturer’s instructions. To remove potential 
traces of genomic DNA, the extracted RNA samples were 
treated with a TURBO DNA-free™ Kit (Ambion, Austin, 
TX, USA) for 30  min at 37  °C. RNA concentration was 
quantified by UV absorption (Nanodrop, LabTech Inter-
national, UK) and RNA quality was assessed using an 
Agilent 2100 Bioanalyzer© and RNA 6000 Nano Kit (Agi-
lent, Santa Clara, CA, USA). For all RNA samples, the 
RIN (RNA integrity number) value was above 8, ensuring 
the high quality of isolated RNA.
Microarray analysis
Gene expression profiles were determined using 
 GeneChip® Human Gene 1.0 ST arrays (Affymetrix, 
Santa Clara, CA, USA) according to the manufacturer’s 
protocols. Briefly, 100  ng of total RNA per sample was 
reverse-transcribed, amplified, fragmented, and labeled 
using the  Ambion® WT Expression Kit and Affymetrix 
 GeneChip® WT Terminal Labeling Kit with included 
quality controls. Hybridization to the microarrays was 
conducted for 17 h at 45 °C in an Affymetrix GeneChip 
Hybridization Oven 640. Following hybridization, the 
microarrays were washed and stained on an Affymetrix 
GeneChip Fluidics Station 450 and scanned on an Affy-
metrix GCS 3000 GeneArray Scanner.
Quality analyses were performed using the Affymetrix 
Expression Console™ Software and standard Affymetrix 
quality metrics. Raw microarray data were background 
corrected, log transformed, and quantile normalized 
using the robust multi-array average (RMA) algorithm as 
implemented in the  Partek® Genomics Suite™ software 
(Partek Inc., St. Louis, MO, USA). The statistical signifi-
cance of the results was estimated by analysis of variance 
(ANOVA). Differentially expressed genes were identified 
using the fold change (FC) of gene expression ratios > 1.5 
and P value< 0.05 corrected for false discovery rate (FDR) 
as significance criteria.
Validation of mRNA levels by RT‑qPCR
To validate the microarray results, the expression levels 
of 10 selected genes in the cultured cells treated with GO 
(compared with cultured cells treated with buffer) were 
quantified by real-time reverse transcription-polymerase 
chain reaction (RT-qPCR). cDNA was synthesized from 
400 ng of total RNA using the QuantiTect Reverse Tran-
scription kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s protocol. Amplification primers were 
designed using the Clone Manager Suite (Sci-Ed Soft-
ware, Morrisville, USA). RT-qPCR assays were carried 
out using the  LightCycler®480 and  LightCycler®480 Fast-
Start SYBR Green I Master (Roche Diagnostics GmbH, 
Germany). All assays were run in triplicate. Quantifica-
tion cycles (Cq) were calculated using the second deriva-
tive method  (LightCycler®480 Software, Roche). The fold 
change in gene expression levels, corrected by efficiency, 
was analyzed using Relative Expression Software Tool 
(REST 2009) (Qiagen; [57]). The expression data were 
normalized to the polymerase (RNA) II (DNA directed) 
polypeptide A (POLR2A) and ribosomal protein L29 
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(RPL29) genes, which in a RefFinder algorithm-based 
selection were the most stable among the 4 candidate 
reference genes tested. All experiments were performed 
according to the MIQE guidelines [58].
Enrichment analysis
The list containing names of genes, the expression of 
which was regulated in GBM cells by GO treatment, was 
annotated with overrepresented (enriched) biological 
terms using the Enrichr tool (http://amp.pharm .mssm.
edu/Enric hr/) [26]. Such terms include: (1) ontologies, 
which are defined groups of biological entities, such as 
“biological processes” or “molecular functions”; (2) tran-
scriptional regulators, which are molecules crucial for 
modulating gene expression; (3) biochemical pathways; 
and (4) hub proteins, which interact with large numbers 
of molecular partners. Enrichr calculates P-values of 
enrichment using Fisher’s Exact Test. Only terms show-
ing the statistical significance of enrichment of at least 
P = 0.05, after adjustment for multiple testing (Benja-
mini–Hochberg method), were considered to be genu-
inely enriched and were included in the results. The 
enrichment method for analysis of transcriptomic data 
is resistant to potential false positive findings, inevitably 
resulting from large scale microarray studies.
Additional files
Additional file 1: Table S1. All probes reporting statistically significant 
difference between GBM cells treated with GO, GN or GR and non-treated 
GBM cells.
Additional file 2: Table 2A. All terms that were identified in enrichment 
analysis of the list of differentially expressed genes responding to GO. 
Table 2B. Non-redundant transcriptional regulators which target genes 
are overrepresented in the list of differentially expressed genes respond-
ing to GO.
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